Jii B. Lee
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.
Journal: Journal for immunotherapy of cancer
Published: February 16, 2026
A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 01, 2026
Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.
Journal: Cancer research and treatment
Published: December 23, 2025
JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 02, 2025
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 13, 2025
Evolving roles of MET as a therapeutic target in NSCLC and beyond.
Journal: Nature reviews. Clinical oncology
Published: June 12, 2025
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 18, 2025
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 20, 2024
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.
Journal: Lung Cancer (Auckland, N.Z.)
Published: August 21, 2024
Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced neutrophilic lung inflammation in tuberculosis.
Journal: Nature communications
Published: August 13, 2024
Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First-Line Chemotherapy.
Journal: Thoracic cancer
Published: July 05, 2024
Foritinib, a type II ROS1 inhibitor for NSCLC.
Journal: The Lancet. Respiratory medicine
Published: June 25, 2024
Last Updated: 09/26/2026